Although it has already been shown that the PI3K/Akt/mTOR pathway is highly active in many B cell malignancies, including DLBCL [24], our study is the first to demonstrate the activation of these growth/survival pathways in a representative DHL-DLBCL cell line. This evidence concerns the gene AKT1 and diffuse large B-cell lymphoma.